Summary of clinical results

AVENE
COMEDOMED Concentré anti-imperfection

Tolerance and efficacy of CLEANANCE COMEDOMED anti-blemish concentrate as a maintenance treatment for facial acne

Tolerance and efficacy of CLEANANCE COMEDOMED anti-blemish concentrate in teenagers and adults as a maintenance treatment for facial acne, under dermatological control
Real-life international cohort study with 12-month follow-up

Population

54 subjects aged 12 to 35 with mild to moderate facial acne (GEA score 1 to 3) and oily skin

Application of CLEANANCE COMEDOMED anti-blemish concentrate

  • 2 applications per day on the face for 1 year

Evaluation criteria

  • Severity of acne (GEA score = Global Evaluation of Acne)
  • Rate of acne relapse (GEA score ≥3 requiring introduction of antiacne treatment)
  • Quality of life questionnaire (Cardiff Acne Disability Index - CADI)
  • Skin tolerance

Results

  • Statistically significant improvement in acne severity score at 6 and 12 months (p<0.001, versus inclusion)
image 1

Evolution of acne severity score (GEA) over 12 months

** p= statistically Highly Significant (p<0.001, versus inclusion)

 

  • Highly significant improvement in the number of inflammatory and non-inflammatory lesions, with effect maintained at 1 year: -53.9% and -61.3% respectively (p<0.0001)
Image 2

Evolution of the number of inflammatory and non-inflammatory lesions (lesion count) over 12 months

** p= statistically Highly Significant (p<0.001, versus inclusion)

 

  • No relapse of acne for 90% of subjectsat 6 months and 85% of subjects at 1 year

  • Highly significant decrease in CADI score after 1 year: -53.7% (p<0.001, versus inclusion)

  • Excellent skin tolerance for 98% of subjects

Conclusion

CLEANANCE COMEDOMED anti-blemish concentrate applied twice daily as a maintenance treatment for 1 year improves acne severity and limits recurrences

Excellent skin tolerance

More summaries of clinical results